|
Agent Type:
|
Synthetic; Small molecule; Direct acting;
|
|
Spectrum of activity:
|
Gram-positive
|
|
Mechanism of action:
|
Cell division inhibitor. FtsZ inhibitor
|
|
Target Pathogen:
|
Active against methicillin-sensitive and methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, and linezolid-resistant Staphylococcus aureus
|
|
Description:
|
Synthetic compound; no cytotoxicity against opossum kidney (mammalian) cell line at 4x and 10x MIC; its carboxamide prodrug is TXH1033
|
|
Institute where first reported:
|
Department of Pharmacology, Rutgers Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, New Jersey 08854, United States
|
|
Year first mentioned:
|
2023
|
|
Development status:
|
Experimental
|